Within the diabetic retinopathy market, Non-proliferative Diabetic Retinopathy accounted for a 67.39% share in 2025, making it the leading type segment. Its leadership is underpinned by the fact that this stage represents the earlier and more commonly identified form of the disease, which brings a larger diagnosed patient pool into routine monitoring and treatment pathways. Clinical management in the diabetic retinopathy market is often initiated at this stage to slow progression and preserve vision, reinforcing the segment’s dominant share through consistent screening-led detection and ongoing care demand.

Proliferative Diabetic Retinopathy is the fastest-growing type segment in the diabetic retinopathy market as the need for more active intervention rises once disease progression reaches advanced stages. Growth is being aided by increasing clinical focus on preventing severe vision loss in high-risk patients, which drives stronger treatment uptake compared with earlier-stage cases that may remain under observation for longer periods. Relative to Non-proliferative Diabetic Retinopathy, this segment gains momentum from the urgency of care and the greater intensity of management required once abnormal blood vessel growth and complications become more pronounced.

Management Segment Analysis: Anti-VEGF (Largest Segment) vs Laser Surgery (Fastest-Growing Segment)

Anti-VEGF held the largest share in the diabetic retinopathy market in 2025, aided by its established role in routine disease management across a broad range of patients requiring vision preservation and retinal stabilization. Its dominant position reflects how widely this approach is integrated into treatment practice, particularly where ongoing therapeutic control is needed without immediately moving to procedural intervention. In the diabetic retinopathy market, this broad clinical applicability helps Anti-VEGF maintain its share by aligning with regular follow-up care and repeat treatment patterns.

Laser Surgery is emerging as the fastest-growing management segment in the diabetic retinopathy market because it becomes increasingly relevant when durable procedural intervention is required for progressing or advanced retinal disease. Its momentum is tied to practical treatment needs in cases where physicians seek more targeted retinal control, especially for patients who may not achieve sufficient outcomes through pharmacologic management alone. Compared with alternatives centered on repeated administration, Laser Surgery is experiencing stronger uptake through its procedural utility in managing disease severity and reducing the risk of further retinal complications.